Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Counsyl | RCV000666647 | SCV000790976 | likely pathogenic | Peroxisome biogenesis disorder type 3B; Peroxisome biogenesis disorder 3A (Zellweger) | 2017-04-18 | criteria provided, single submitter | clinical testing | |
| Labcorp Genetics |
RCV001237704 | SCV001410477 | pathogenic | Peroxisome biogenesis disorder 3A (Zellweger) | 2023-05-11 | criteria provided, single submitter | clinical testing | This variant disrupts a region of the PEX12 protein in which other variant(s) (p.Leu297Thrfs*12) have been determined to be pathogenic (PMID: 9792857, 14571262, 21031596, 25287621, 26094004). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 551557). This variant has not been reported in the literature in individuals affected with PEX12-related conditions. The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This sequence change creates a premature translational stop signal (p.Trp263*) in the PEX12 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 97 amino acid(s) of the PEX12 protein. |
| Baylor Genetics | RCV001237704 | SCV005055254 | likely pathogenic | Peroxisome biogenesis disorder 3A (Zellweger) | 2023-11-29 | criteria provided, single submitter | clinical testing |